Susan Percy Ivy, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

George Washington University School Of Medicine And Health Sciences - Washington DC
Rank: Associate Professor
Years:


Rank: Associate Professor
Years: 1989-Present

None Reported

Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Expert Opin Investig Drugs
28:771–85
Date: 01 2019

Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer.
Cancer.
126:2139–45.
Date: 01 2020

Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
Cancer Chemother Pharmacol
86:535–45.
Date: 01 2020

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Clin Cancer Res.
26:5329–37.
Date: 01 2020

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
J Clin Oncol.
38:2407–17.
Date: 01 2020

Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC-MS/MS.
J Pharm Biomed Anal.
189:113464.
Date: 01 2020

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
Ann Oncol.
31:590–8.
Date: 01 2020

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
Cancer Cell.
39:38–53.e7
Date: 01 2021

Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia
Blood
blood.2020009688.
Date: 01 2021

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
J Natl Cancer Inst.
113:27–37
Date: 01 2021